As with other inhibitors of HMG-CoA reductase. the incidence of side effects is mainly dose-dependent.
Classification of the incidence of adverse events according to the recommendations of the World Health Organization (WHO):
very often ≥1 / 10;
often from ≥ 1/100 to <1/10;
infrequently from ≥ 1/1000 to <1/100;
rarely from ≥ 1/10000 to <1/1000;
very rarely <1/10000. including individual messages;
the frequency is unknown - it is not possible to establish the frequency of occurrence from the available data.
From the immune system:
rarely - reactions of hypersensitivity, including angioedema.
From the endocrine system:
often - type 2 diabetes.
From the central nervous system:
often - headache, dizziness;
very rarely - loss or loss of memory;
frequency unknown - peripheral neuropathy.
From the respiratory system:
frequency unknown - cough, dyspnea.
From the digestive system:
often - constipation, nausea, abdominal pain;
rarely - pancreatitis;
frequency is unknown - diarrhea.
From the skin:
infrequently - itchy skin, skin rash, hives;
frequency is unknown - Stevens-Johnson syndrome.
On the part of the organs of hematopoiesis:
frequency unknown - thrombocytopenia.
From the side of the musculoskeletal system:
often - myalgia;
rarely - myopathy (including myositis), rhabdomyolysis;
very rarely - arthralgia;
frequency unknown - immuno-mediated necrotizing myopathy.
When rosuvastatin was used in all doses and, in particular, when doses exceeding 20 mg were given, the following effects on the musculoskeletal system were reported: myalgia, myopathy (including myositis), in rare cases rhabdomyolysis with or without acute renal insufficiency.
A dose-related increase in creatine phosphokinase (CK) activity is observed in a small number of patients taking rosuvastatin. In most cases, it was insignificant, asymptomatic and temporary. In the case of increased activity of CK (more than 5 times compared with the upper limit of the norm) therapy should be suspended (see section "Special instructions").
From the urinary system:
very rarely - hematuria;
often - proteinuria.
Changes in the amount of protein in the urine (from absence or trace amounts to ++ or more) are observed in less than 1% of patients receiving rosuvastatin in a dose of 10-20 mg, and approximately 3% of patients receiving 40 mg of rosuvastatin.A slight change in the amount of protein in the urine was noted with the use of rosuvastatin in a dose of 20 mg. In most cases, proteinuria decreases or disappears during therapy and does not indicate the onset or progression of an existing kidney disease.
From the side of the liver:
rarely - increased activity of "liver" transaminases;
very rarely - jaundice, hepatitis.
With the use of rosuvastatin, a dose-dependent increase in the activity of "hepatic" transaminases in a small number of patients is observed. In most cases, it is insignificant, asymptomatic and temporary.
From the reproductive system and breast:
frequency unknown - gynecomastia.
Laboratory indicators:
the frequency is unknown - an increase in the concentration of glucose, bilirubin, the activity of gamma-glutamintranspeptidase, alkaline phosphatase, thyroid dysfunction.
Other:
often - asthenic syndrome;
frequency unknown - peripheral edema.
With the use of some statins, the following side effects have been reported: depression, sleep disturbances, including insomnia and nightmarish dreams, sexual dysfunction, hyperglycemia, increased concentrations of glycosylated hemoglobin.
Single cases of interstitial lung disease have been reported (especially with prolonged use of statins).